|1.||Hu, Zhongyi: 4 articles (01/2013 - 12/2003)|
|2.||Saydoff, Joel A: 4 articles (01/2013 - 12/2003)|
|3.||von Borstel, Reid W: 3 articles (12/2006 - 12/2003)|
|4.||Garcia, Rolando A G: 3 articles (12/2006 - 12/2003)|
|5.||von Borstel, Reid: 2 articles (01/2013 - 07/2006)|
|6.||Sheng, Jin: 2 articles (01/2013 - 12/2006)|
|7.||Liu, Liansheng: 2 articles (12/2006 - 12/2005)|
|8.||Gonzalez, Alexis: 2 articles (12/2006 - 12/2005)|
|9.||Pei, Jiong: 1 article (01/2013)|
|10.||Sun, Grace Y: 1 article (01/2013)|
07/01/2006 - "Female BALB/c mice (Colon 26 adenocarcinoma) were treated with 5-FU with PN401 to define the MTD, and pharmacokinetic analyses were done. "
11/01/2006 - "Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study."
11/01/2006 - "From February, 2001 to September, 2002, the Southwest Oncology Group (SWOG) accrued 65 patients with advanced gastric adenocarcinoma to a phase II trial of weekly 5-FU, leucovorin, and the orally-administered uridine analog PN401. "
04/01/1997 - "Thirty-eight patients with advanced cancer received PN401 and FU. "
04/01/1997 - "Patients with advanced cancer received oral PN401 as either a suspension or a tablet in escalating doses. "
04/01/1997 - "Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer."
|4.||Huntington Disease (Huntington's Disease)
12/01/2006 - "Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease."
01/01/2013 - "Uridine prodrug PN401 has been shown to have neuroprotective effects in models of Parkinson's disease and Huntington's disease. "
12/19/2003 - "Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease."
12/01/2006 - "Previously, uridine pro-drug 2',3',5'-tri-O-acetyluridine (PN401) was shown to be protective in the mitochondrial complex II inhibitor 3-nitropropionic acid model of Huntington's disease (HD). "
|5.||Neurodegenerative Diseases (Neurodegenerative Disease)
|3.||Leucovorin (Folinic Acid)